Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Investor presentations
ObsEva to participate in Cantor Global Healthcare Conference October 2-4 2019
New York City
Friday, October 4 at 7:45 a.m. Eastern time (ET).
The H.C. Wainwright 21st Annual Global Investment in NYC – September 10th 2019
Wedbush Presentation August 2019 in NYC
KOL Event in NYC July 2019
Jefferies Healthcare Conference Presentation – June 2019
ObsEva Investor Presentation – April 2019
ObsEva Short Report 2018
Press Releases
ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy
press release
October 11, 2019
Once-daily oral Linzagolix doses of 75 mg and 100 mg without hormonal add-back therapy could lead to symptom relief of…
Read moreObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA
press release
October 9, 2019
Geneva, Switzerland and Boston, MA – October 9, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage…
Read moreObsEva SA to Participate in Cantor Global Healthcare Conference October 2-4, 2019
press release
September 27, 2019
Geneva, Switzerland and Boston, MA – September 27, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2019
May 8, 2019
ObsEva Annual General Meeting 2018
May 9, 2018
Upcoming Events
ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy
Event
October 17, 2019
Stock Information
Latest Press Release
ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy
Once-daily oral Linzagolix doses of 75 mg and 100 mg without hormonal add-back therapy could lead to symptom relief of…
Read moreInvestor Contact
Media Contact
Media Switzerland & Europe
Christophe Lamps
Dynamics Group
+41 79 476 26 87
Media United States
Marion Janic
RooneyPartners LLC
+1 212-223-4017
Contacts
Sign up for news
